Osteosarcoma in dogs

Osteosarcoma (OSA) is the most common type of bone cancer in dogs. It most often occurs in bones bordering the shoulder, wrist, and knee. Appendicular Osteosarcoma, or osteosarcoma of the limbs, accounts for the majority of bone cancer cases. This form of cancer tends to be aggressive and frequently spreads to the lungs and other bones.

Common Symptoms

  • Limping, or lameness, is the most common sign of this disease

  • Spontaneous fractures of the bone

  • Swelling at the site of the cancer

  • The typical symptom for dogs with mandibular (lower jaw bone) and orbital site tumors (behind the eye) is dysphasia (difficulty swallowing). Dogs with cranial (skull) or vertebral tumors will present with neurologic deficits. Dogs with pelvic masses may have dyschezia (difficulty defecating) as their primary symptom.

Causes and Risk Factors

The cause of osteosarcoma in dogs is unknown. However, there are some contributing risk factors:

  • Osteosarcoma usually occurs in middle-aged or elderly large and giant breed dogs, particularly those who have experienced rapid growth, tend to be at higher risk, especially Rottweilers and Scottish Deerhounds. 

  • Males tend to have a slightly higher risk of getting osteosarcoma.

  • Dogs that are spayed or castrated at an early age.


FidoCure can help create a personalized treatment approach for dogs with osteosarcoma. 


Historically, surgery, chemotherapy, and radiation have been the most common forms of treatment. However, targeted therapies are a more advanced treatment option. FidoCure, from The One Health Company, enables your vet oncologist to understand the exact genetic mutation causing your dog’s cancer and provide an individualized, targeted treatment plan leveraging the latest science available in oncology. 

DISCLAIMER: FidoCure™ is a leader in oncology research for dogs, and our team is committed to the breakthroughs in cancer biology to evolve canine cancer care, with each patient improving the outcomes for all future canine cancer patients. We use our best efforts to inform the veterinarian, who then decides which option is best for their patient. The therapies that veterinarians may prescribe and order from compounding pharmacies after receiving genetic test results from FidoCure, may constitute extra-label uses of those drugs. FidoCure is continuing to gather research data in support of novel oncology therapeutics in dogs.

  • Instagram - White Circle
  • Twitter - White Circle
  • Facebook - White Circle

© One Health Company 2019